Physician profile
Augustine George
NPI 1346534542
$15,196.98
in general payments reported to CMS, 2019-2025
23 companies · $2,796 in 2025
The $2,796 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $9.23 · 2021: $705 · 2022: $2,036 · 2023: $5,104 · 2024: $4,409 · 2025: $2,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,636 · Food and Beverage: $4,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,636.23 |
| Food and Beverage | $4,672.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,972.51 | 2021-2025 | Corevalve Evolut R, Micra |
| Philips North America LLC | $2,062.99 | 2022-2024 | (Bh4) Igt Devices Undivided |
| Edwards Lifesciences Corporation | $2,043.48 | 2021-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $2,014.62 | 2019-2024 | Versacross Access Solution |
| Penumbra, INC. | $1,526.00 | 2023 | Indigo System, Penumbra System |
| Terumo Medical Corporation | $1,507.19 | 2023 | Glidesheath Slender |
| Abbott Laboratories | $1,113.14 | 2019-2025 | Ultreon, Cardiomems, Coroflow |
| Medical Device Business Services, INC. | $793.70 | 2024 | Carto 3 |
| Novartis Pharmaceuticals Corporation | $173.28 | 2021-2025 | |
| Shockwave Medical, INC | $159.97 | 2025 | |
| Cvrx, INC. | $149.46 | 2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.80 | 2022-2024 | Lifevest |
| Amgen INC. | $126.76 | 2019-2025 | Otezla, Repatha |
| Abiomed | $122.58 | 2024 | Impella |
| Merck Sharp & Dohme LLC | $61.40 | 2022-2023 | Verquvo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $44.50 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $42.02 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $22.03 | 2024 | |
| Astellas Pharma US INC | $19.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.49 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $17.45 | 2023 | Eliquis |
| Cardiovascular Systems INC. | $9.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.